Life-saving cancer drugs don't come cheap, but research shows some or most of the medicine isn't actually being used to treat cancer patients.
Instead, a new study finds that Medicare and insurance companies waste roughly $3 billion a year on cancer medicine that is ultimately thrown away. This happens when pharmaceutical companies distribute the drugs in vials that contain a larger dose than necessary for the patients who have been prescribed them. What they don't use, they trash.
The study, published in the BMJ, found that the average patient prescribed Kyprolis, a drug for Myeloma, gets a dose of 34 mg, 26 mg of which is wasted. The researchers estimated that the value of the tossed medication is $231 million.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
- Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events
- Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
Already have an account? Sign In
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
